NCT06768905View on ClinicalTrials.gov

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2030

Conditions
Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma
Interventions
DRUG

Iomab-B

single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion.

DRUG

CAR-T cell

CAR-T cell therapy

Trial Locations (1)

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Actinium Pharmaceuticals
All Listed Sponsors
collaborator

Actinium Pharmaceuticals

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER